Omega 3 Prescription Drugs Market Set To Grow From $1.92 Billion In 2026 To $2.8 Billion By 2030 At A CAGR Of 10%
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Omega 3 Prescription Drugs Market Revenue Growth Supported By A CAGR Of 2.8% Through 2030
The omega 3 prescription drugs market has experienced notable expansion over the recent past. Its value is projected to rise from $1.75 billion in 2025 to $1.92 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.9%. Several factors contributed to this growth during the historical period, including a high incidence of hypertriglyceridemia, greater awareness surrounding cardiovascular diseases, an expanding elderly demographic, the accessibility of prescription omega-3 medications, and progress in clinical research and trials.
The omega 3 prescription drugs market is anticipated to experience robust expansion over the coming years, projected to reach $2.81 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.0%. This forecasted growth is driven by factors such as progress in precision medicine, a growing preference for tailored treatments, the adoption of digital health technologies, opportunities in emerging markets, and developments in omega-3 drug formulations. Key trends shaping this period include the creation of customized omega-3 therapies, an uptick in clinical research for omega-3 products, advances in cardiovascular risk management offerings, broader availability of prescription omega-3 medications, and improved synergy between nutraceuticals and pharmaceuticals.
Download A Free Sample Report For Comprehensive Market Insights:
Omega 3 Prescription Drugs Market Opportunity Drivers: What Is Creating New Revenue Potential?
The growing prevalence of cardiovascular diseases (CVDs) is anticipated to fuel expansion in the omega-3 prescription drug market. Elevated blood triglyceride levels—a fatty-like substance—are associated with a heightened risk of cardiovascular conditions, and omega-3 supplements play a role in managing and reducing these levels. For example, data released in August 2025 by the National Institutes of Health, a US government agency, indicates that from 2025 to 2050, cardiovascular prevalence is expected to climb by 90%, mortality rates by 73%, and disability-adjusted life years (DALYs) by 55%, with annual deaths rising from 20.5 million to 35.6 million. Consequently, the increasing incidence of cardiovascular diseases (CVDs) is a key factor driving the growth of the omega-3 prescription drug market.
Omega 3 Prescription Drugs Market Segment Outlook: Which Categories Are Expanding The Fastest?
The omega 3 prescription drugs market covered in this report is segmented –
1) By Drug Type: Vascepa, Lovaza, Other Type
2) By Application Type: Hypertriglyceridemia, Other Application Type
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Vascepa: Pure EPA (Eicosapentaenoic Acid) Formulation, Indications For Cardiovascular Risk Reduction
2) By Lovaza: Combination Of EPA And DHA (Docosahexaenoic Acid), Indications For Hypertriglyceridemia Management
3) By Other Types: Epanova (Omega-3 Carboxylic Acids), Omega-3 Formulations In Clinical Trials, Other Prescription Omega-3 Products
Omega 3 Prescription Drugs Market Innovation Trends Driving Future Development
Major players in the omega-3 prescription drug space are introducing new product offerings, such as capsules, which function by lowering the amount of triglycerides produced by the body. A capsule is a dosage format for pharmaceuticals or dietary supplements, typically composed of a gelatin-based or similar outer shell that encloses a measured amount of medication, nutrients, or other actives, providing a convenient and easy-to-swallow option. For example, in March 2023, Hikma Pharmaceuticals, a UK-based multinational that manufactures generic and licensed pharmaceutical products, introduced Icosapent Ethyl Capsules (0.5 g) in the United States. This product is intended to lower triglyceride levels in adults suffering from severe hypertriglyceridemia, and it contains eicosatetraenoic acid (EPA), recognized for its ability to reduce triglycerides. This market introduction advances treatment options for severe hypertriglyceridemia, addresses the growing need for high-quality pharmaceutical-grade omega-3 formulations, and is consistent with the industry’s emphasis on developing effective therapies for conditions such as elevated triglyceride levels.
Omega 3 Prescription Drugs Market Key Companies And Competitive Benchmarking
Major companies operating in the omega 3 prescription drugs market are Pfizer Inc., Sanofi S.A., Amarin Corporation plc, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, BASF SE, DSM Nutritional Products, AbbVie Inc., Eli Lilly and Company, Bayer AG, Shire Pharmaceuticals, Mylan NV, Teva Pharmaceutical Industries Ltd., Horizon Therapeutics, Kyowa Kirin Co. Ltd., Sumitomo Pharma Co. Ltd.
Access The Complete Omega 3 Prescription Drugs Market Report:
Omega 3 Prescription Drugs Market Regional Analysis And Leading Geography
North America was the largest region in the omega 3 prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omega 3 prescription drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
